Deal worth $4BN sealed as Amgen buys biopharma ChemoCentryx

A company producing drugs including TAVNEOS to treat autoimmune diseases, plus others dealing with inflammatory disorders and cancer has been bought by biopharmaceutical company, Amgen for $52 per share.

ChemoCentryx and Amgen have entered a definitive agreement worth approximately $3.7 billion.

Robert Bradway, chairman and chief executive officer at Amgen, said: “The acquisition of ChemoCentryx represents a compelling opportunity for Amgen to add to our decades-long leadership in inflammation and nephrology with TAVNEOS, a transformative, first-in-class treatment for ANCA-associated vasculitis.

Serious disease

“We are excited to join in the TAVNEOS launch and help many more patients with this serious and sometimes life-threatening disease for which there remains significant unmet medical need. We also look forward to welcoming the highly skilled team from ChemoCentryx that shares our passion for serving patients suffering from serious diseases.”

TAVNEOS is an orally administered selective complement component 5a receptor inhibitor. It was approved by the U.S. Food and Drug Administration (FDA) in October 2021 as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis,

The post Deal worth $4BN sealed as Amgen buys biopharma ChemoCentryx appeared first on

© Labiotech UG and Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and with appropriate and specific direction to the original content.


About the Author: Biotech Today

You might like